Neeraj Agarwal, MD, discusses the results of the phase 3 SWOG S1216 trial, in which patients with metastatic hormone-sensitive prostate cancer (mHSPC) received ADT plus the novel agent TAK-700 or bicalutamide. Progression-free survival and PSA response were improved with TAK-700. Median overall survival was about 11 months higher in the TAK-700 arm, but the difference did not reach statistical significance per the study design.
Agarwal notes, however, that the median OS was significantly higher in the control arm than other contemporary trials. This led to a posthoc analysis which found that over three-fourths of the control arm had received subsequent life-prolonging therapies. Based on the findings of the main and posthoc analyses, Agarwal concludes, “These results show that early intensification of ADT in the mHSPC setting in combination with access to life-prolonging therapies in the metastatic castration-resistant prostate cancer setting is likely going to result in unprecedented overall survival benefits in our patients.”
Agarwal is a professor of Medicine at the Huntsman Cancer Institute, University of Utah. Reference: J Clin Oncol 39, 2021 (suppl 15; abstr 5001). doi: 10.1200/JCO.2021.39.15_suppl.5001